8-Aminoguanine Effects on Paclitaxel-Induced Neuropathy in Preclinical Model

A preclinical study investigating the hypothesis that chemotherapy-induced peripheral neuropathy (CIPN) involves increased purine nucleoside phosphorylase (PNPase) activity. The research tested the endogenous PNPase inhibitor 8-aminoguanine (8-AG) for preventing and reversing paclitaxel-induced mechanical hypersensitivity and nerve fiber loss in a model. Findings suggest PNPase inhibition reduces oxidative injury and cellular damage associated with paclitaxel treatment.

Use Cases

• Validate the PNPase activity hypothesis for CIPN based on biochemical and behavioral outcome measures.
• Assess the therapeutic potential of 8-aminoguanine based on its effects on mechanical hypersensitivity and intra-epidermal nerve fiber density.
• Investigate molecular pathways of nerve regeneration based on changes in GAP-43, Mst3b, Nogo-A, and NMNAT2 expression.
• Correlate pro-inflammatory purine levels and oxidative stress biomarkers with neuropathic symptom severity.

Strengths

• Hypothesis-driven experimental design testing prevention and reversal of neuropathy.
• Includes multiple outcome measures: behavioral (mechanical hypersensitivity), histological (IENF density), and molecular (gene/protein expression, metabolite levels).
• Last updated 2026-06-01 13:28:06, indicating recent availability.

Limitations

• Row count and dataset scale are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data appears to be from a specific, controlled animal model, which may limit generalizability.

Provenance

Source

Harvard Dataverse

Collection Method

Preclinical laboratory research involving paclitaxel administration and 8-aminoguanine treatment in a model.

Freshness

Last updated 2026-06-01 13:28:06